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Abstract 
Background: Careful assessment of reasons for discontinuation of active surveillance (AS) is 
required for men with prostate cancer (PCa).  
Objective: Using Movember’s Global Action Plan Prostate Cancer Active Surveillance initiative 
(GAP3) database, we report on reasons for AS discontinuation.  
Design, Setting, and Participants: We compared data from 10,296 men on AS from 21 
centres across 12 countries.  
Outcome Measurements and Statistical Analysis: Cumulative incidence methods were used 
to estimate the cumulative incidence rates of AS discontinuation. 
Results and Limitation: During 5 years follow-up, 27.5% (95%CI: 26.4%-28.6%) men showed 
signs of disease progression, 12.8% (95%CI: 12.0%-13.6%) converted to active treatment 
without evidence of progression, 1.7% (95%CI: 1.5%-2.0%) continued to watchful waiting, and 
1.7% (95%CI:1.4%-2.1%) died from other causes. Of the 7,049 who remained on AS, 2,339 had 
follow-up >5 years, 4,561 had <5 years, and 149 were lost to follow-up. Cumulative incidence of 
progression was 27.5% (95%CI: 26.4%-28.6%) at 5 years and 38.2% (95%CI: 36.7%-39.9%) at 
10 years. A limitation is that not all centres were included due to limited information on reason 
for discontinuation and limited follow-up.  
Conclusion: Our descriptive analyses of current AS practices worldwide showed that 43.6% of 
men drop out of AS during 5 years follow-up, mainly due to signs of disease progression. 
Improvements in selection tools for AS are thus needed to correctly allocate men with PCa to 
AS – which will also reduce discontinuation due to conversion to active treatment without 
evidence of disease progression.  
Patient summary: Our assessment of a worldwide database of men with PCa on AS shows 
that 43.6% drop out of AS within 5 years, mainly due to signs of disease progression. Better 
tools are needed to select and monitor men with PCa as part of AS.   
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Introduction 
About two decades ago the concept of active surveillance (AS) was introduced as a 
management strategy for men with low-risk prostate cancer  (PCa) [1]. Men are monitored 
closely through repeated prostate-specific antigen (PSA) measurements, biopsies, and 
potentially also Magnetic Resonance Imaging (MRI), with the intention to start curative 
treatment when their PCa is reclassified to higher risk due to signs of  progression ( i.e. clinical 
or pathological) and minimise the harm caused by overtreatment of indolent cancer [2]. 
However, even though AS has no long-term physical morbidity, studies continue to report that 
1.6% to 38% of men opt out of AS, often with no or little evidence of disease progression, within 
5 years [3]. Thus, men embarking on AS are likely to transition to an alternative strategy within a 
decade – which highlights the need for more insight into AS protocols [1, 4].  
 
Careful assessment of reasons for discontinuation of AS is required, especially since treatment 
pathways for men with low-risk PCa vary by country and are managed differently in various 
health care systems [5, 6]. It is unclear whether a decrease in health-related quality of life in 
men on AS precipitates their transition to radical treatment or whether this is driven by the 
distress over disease progression, physiological symptoms, or the burden of age. Most studies 
are small and with short follow-up [7-10]. A better understanding of reasons for opting out of AS 
is thus needed to help define a management strategy for AS. 
 
Hence, in 2014 the Movember Foundation launched the Global Action Plan Prostate Cancer 
Active Surveillance initiative (GAP3), which covers the largest centralised PCa AS database to 
date. Its primary goal is to create a global consensus with uniform guidelines on the selection 
and monitoring of men with low risk PCa [11]. Here, we report on adherence to AS and the 
reasons for discontinuation by comparing data from 10,296 men on AS from 21 different centres 
across 12 different countries.  
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Methods 
Study population 
Between 2014 and 2016, the global GAP3 database was created by combining patient data 
from established AS cohorts worldwide. Requirements for participation included, amongst 
others, ethical approval for sharing digital patient data in a centralized global database, and an 
active registry of AS patients over the last two years or more, including at least ~50 patients 
annually. To date, 25 centres from the USA, Canada, Australasia, the UK and Europe fulfilled 
the requirements for participation and joined the initiative [11] resulting in data for a total of 
15,101 men on AS. For the current study, we excluded 3,084 patients from Dublin, MDACC, 
Toronto and MUSIC as these centres did not distinguish between progression and anxiety 
events. Furthermore, to ensure as much homogeneity in our AS cohort as possible, we only 
included men with a Gleason Grade Group of 1, leaving 10,296 patients for the final analysis. 
Each institution obtained institution ethical approval and signed a Movember End User License 
Agreement, Access Rights Principles Agreement, and the commonly agreed upon GAP3 
analytical plan.  
 
Although there are many variations in existing protocols, most agreed that the most suitable 
patients for AS are those with age>18, pre-treatment clinical stage T1-T2, serum PSA ≤10 
ng/ml, a biopsy Gleason Grade Group of 1 or 2, and a maximum of two tumour-positive biopsy 
core samples. The AS inclusion criteria for the 25 centres are shown in supplemental Table 1 
[11]. Some protocols included PSA density (most often using a cut-off of 0.2 ng/ml), the 
maximum extent of cancer per core (most often using a cut-off of 50%), life expectancy of >10 
years and adequate biopsy sampling as inclusion criteria for AS. An overview of contemporary 
worldwide AS practices across the world (and included in GAP3) can also be found in the 
systematic review by Kinsella et al [3] and the cohort profile of the GAP3 database [5].  
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Following initiation of AS, almost all protocols recommended serial measurements (with a 
variation in time-intervals) of serum PSA levels, digital rectal examination (DRE) and 
surveillance biopsy sampling in order to identify pathological progression. Several protocols 
considered MRI for routine use in AS, again with many differences between recommended 
frequency. An overview of the AS follow-up protocols of the 25 institutes included in GAP3 is 
given in Supplemental Table 2 [11].   
 
In addition to baseline criteria for selection and monitoring of AS, the GAP3 database also 
contains information on discontinuation of AS (i.e. the reasons for stopping AS), and potential 
following treatments (e.g. radical prostatectomy (RP)) and cause of death. Each centre reports  
for each patient an event time, defined as the time from his AS initiation to discontinuation of AS 
due to: ‘Convert to watchful waiting’, ‘Clinical progression’, ‘Pathological progression’, ‘Clinical 
and Pathological progression’, ‘PSA progression (PSA-DT < 3 years)’, ‘Other PSA kinetics’, 
‘Patient choice/Anxiety’, ‘Doctors Anxiety’, ‘Radiological progression’, ‘Died’, ‘Lost to FU’, 
‘Other/Unknown’ or ‘Still on active surveillance’. These events are defined according to the 
centres own criteria. We used the following coding for defining signs of disease progression: 
‘clinical and pathological progression’, ‘clinical progression’, ‘other PSA kinetics’, ‘pathological 
progression’, ‘PSA progression’, and ‘radiological progression’. If the reason for discontinuation 
was classified as ‘other/unknown’, but the ‘pathological progression status’ reported at time of 
AS discontinuation was ‘Gleason Grade Group 3 or higher’ or the ‘clinical progression status’ 
was ‘cT3 or higher’ or ‘PSA progression status’ was ‘PSA>20’, the reason for discontinuation 
was also classified as signs of disease progression. The term “sign of disease progression” as 
used in this manuscript can thus refer to risk reclassification or disease progression as such. 
Conversion to active treatment without evidence of disease progression includes those patients 
for whom there was no information on specific discontinuation or disease progression 
(according to the criteria described above) and for whom specific treatment information was 
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available, as well as those for whom the reason for discontinuation was registered as ‘doctor’s 
anxiety’ or ‘patient’s choice/anxiety’. The distribution of different types of active treatment has 
been described in detail in our recently published cohort profile [11].  
 
Statistical methods 
 
Descriptive statistics were used to summarize patient characteristics. The cumulative incidence 
method was used to estimate the rates of each event for discontinuation of AS. Cox proportional 
hazards regression analyses were used to estimate hazard ratio for various reasons of 
discontinuation based on age, PSA and number of positive biopsy cores. To account for the 
heterogeneity between centres, these models used centre as a strata. R version 3.3.2 (The R 
Foundation for Statistical Computing, Vienna, Austria) was used to perform all analyses.  
 
Results 
 
Table 1 shows the distribution of men on AS included in this study according to patient and 
tumour characteristics, by outcome at 5 years of follow-up. During 5 years follow-up, 27.5% 
(95%CI: 26.4%-28.6%) men showed signs of disease progression, 12.8% (95%CI: 12.0%-
13.6%) converted to active treatment without evidence of progression, 1.7% (95%CI: 1.5%-
2.0%) continued to watchful waiting, and 1.7% (95%CI:1.4%-2.1%) died from other causes. Of 
the 7,049 men who remained on AS during follow-up, 2,339 men had a follow-up of more than 5 
years, 4,561 men had less than 5 years of follow-up, and 149 men were lost to follow-up. 
Hence, at 5 years of follow-up, the cumulative incidence rate of men remaining on AS was 
56.4% (95%CI: 55.2%-57.6%) and 43.6% (95%CI: 42.4%-44.8%) were lost to follow-up or 
discontinued AS. Furthermore, the distribution of outcomes and tumour characteristics per 
participating centre are shown in Table 2 and Supplementary Table 3.  
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The cumulative incidence of signs of disease progression was 27.5% (95%CI: 26.4% - 28.6%) 
at 5 years and 38.2% (95%CI: 36.7% - 39.9%) at 10 years. Figure 1 shows the cumulative 
incidence for discontinuation based on the different events: signs of progression, conversion to 
active treatment without evidence of progression, watchful waiting, death, and still on AS. An 
increase in discontinuation can be observed after one year, with the largest proportion being 
due to signs of disease progression and conversion to active treatment without evidence of 
progression. Moreover, it is worth noting that the proportion of men dying from other causes 
increased gradually throughout the follow-up, which reflects the real world setting of this 
database. Finally, it can be seen that the proportion of men converting to active treatment 
without evidence of progression remained stable from about 7 years onwards; a similar trend 
was observed for conversion to watchful-waiting. To further understand how patient 
characteristics may affect discontinuation of AS, we generated a forest plot specifically focused 
on the effects of age (in decade), PSA, and >1 positive biopsy cores (Figure 2). As expected, 
the strongest positive association is seen for age with transferring to watchful waiting and non-
PCa death. Furthermore, >1 positive biopsy core positively associates with progression and 
non-PCa death.  
 
Figure 3 shows the cumulative incidence for discontinuation for each centre included in the 
GAP3 database. For all centres, an increase in signs of disease progression was also be 
observed after one year, but the slope of this increase varied substantially by centre. 
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Discussion 
Based on data from the largest AS database in the world, we observed that after about 5 years 
of follow-up, about 56.4% of men were still on AS. Substantial variation by centre was observed, 
but the main reasons for discontinuation were signs of disease progression (27.5% of men) and 
conversion to active treatment without evidence of disease progression (12.8% of men).  
 
As shown in a recent systematic review by Kinsella et al. many factors influence men’s 
adherence to AS on multiple levels [12]. Their thematic assessment of barriers and facilitators 
for adherence to AS identified many key themes: (1) patient- and tumour factors (age, co-
morbidities, knowledge, education, socioeconomic status, family history, grade, tumour volume, 
fear of progression/side-effects); (2) family and social support; (3) provider (specialty, 
communication, attitudes); (4) healthcare organisation (geography, type of practice) and (5) 
health policy (guidelines, year, awareness)[12]. Interestingly, this systematic review observed 
that even though a number of studies have shown that emotional distress is relatively high in 
men at the time of their PC diagnosis [13, 14], anxiety in men on long-term AS has been 
generally reported as favourably low. More studies have suggested that anxiety in men on AS 
reduces [15-17] or remains the same over time [8, 17-22].  
 
Our findings of a 43.6% drop-out after about 5 years are in line with previous estimations 
 [23]. However, the proportion of men opting out without evidence for progression was only 12.8%. 
The variation observed between different institutions shows rather distinct patterns with respect 
to the proportion of men dropping out due to progression and the proportion of men dropping out 
due to conversion to active treatment without evidence of disease progression. However, part of 
the reason why the proportion of drop out due to conversion to active treatment without evidence 
of disease progression was largest in MSKCC, Singapore, Baden and Goteborg may be explained 
by the fact that their median follow-up was about three to four years as compared to one to two 
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years in most other centres. Nevertheless, the data from other centres with also lengthier follow-
up such as Hopkins, Valencia and UCSF still showed the largest proportion of discontinuation 
due to disease progression. In this context, it was also interesting to note that the proportion of 
men converting to active treatment without evidence of progression in our database remained 
stable after about 7 years. It can be speculated that more anxious men (and clinicians) were more 
likely to make the decision about discontinuing AS during the first years. It might suggest that 
more emphasis on education and support is required during these first years on AS [12]. 
Surprisingly, the proportion of watchful-waiting also stabilised after seven years, which is 
unexpected as the population is growing older. Again, this observation might be due to different 
practices across centres.  
 
The rather large proportion of drop-outs due to signs of disease progression also highlights the 
need for better inclusion/exclusion criteria, better markers of stable disease, and better outcome 
measures. For instance, a recent review by Nowinski et al. showed the need for novel approaches 
of classification, including molecular features, to direct therapy for men with low-grade prostate 
cancer, especially men on AS [24]. They concluded that by combining GWAS data with gene 
expression and structural rearrangements, risk alleles were identified that could provide a new 
basis for developing a prognostication tool to guide therapy for men with early prostate cancer 
[24, 25].  
 
Moreover, the use of MRI as a tool to risk-stratify men with low-risk PCa has been emerging 
over time. A study by Thurthle et al. evaluated data from 157 men enrolled on AS using a 
protocol including multiparametric MRI and noted low progression and treatment conversion 
rates [26]. Changes in mpMRI findings were found to be the principle trigger for detecting 
progression by imaging alone or pathologically. In addition, the recent findings of the PROMIS 
trial, which was based on men with PSA concentrations up to 15 ng/mL, with no previous 
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biopsy, have shown us that MRI identified nearly all men with clinically significant prostate 
cancer (93%) versus the current practice standard (trans-rectal biopsy), which identified only 
48% [27]. The endotype generated by a positive MRI was positively associated with grade and 
volume and contained cancer in most cases (Likert ≥4=92%; Likert≥3=60%). An update of the 
current Movember GAP3 database with information on MRI images will hence provide us more 
insight into the use of MRI as a selection and monitoring tool for AS.   
 
In addition to genetics and MRI, several studies have also investigated the use of serum 
biomarkers as a tool to monitor men on AS. However, a recent systematic review by Loeb and 
Tosoian [28] concluded that very few markers have longitudinal results available yet for men on 
AS – indicating an important area for future research where the GAP3 database will be able to 
contribute. Furthermore, simple changes in clinical assessment have been proposed as a strategy 
to reduce rates of discontinuation of AS. Bokhorst et al. has, for example, shown that the number 
of positive biopsies should no longer be used to trigger immediate active treatment, but rather 
indicate further investigation to confirm the suspicion of higher risk disease [29].  
 
The GAP3 database is a unique resource covering data from all over the world. Some limitations 
exist, resulting in not all centres being included in these analyses due to the lack of information 
on reason for discontinuation and limited follow up.  However, even after a follow-up of 5 years 
we could already observe clear patterns with respect to reasons for discontinuation. The 
heterogeneity in study protocols and data collection across centres can be seen as a limitation, 
however we would like to argue that it is this real world setting that adds value to our 
understanding of AS. As outlined by PIONEER, the big prostate cancer data consortium of the 
European Association of Urology, combining and analysing the patient records of men diagnosed 
with prostate cancer can enable healthcare systems to provide more efficient outcome-
driven patient-centred interventions [30]. By providing data from a wide variety of centres, GAP3 
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has the power to transform the perspective of all relevant stakeholders. Movember has recently 
also allocated additional funding to maintain the database and update the clinical data annually 
thereby prolonging follow up time.  Furthermore, this provides the opportunity to collect evidence 
on imaging (MRI), molecular (genomics) markers, patient-related outcomes and more. In addition, 
it is worth noting that qualitative data on its own will not be sufficient to answer the question about 
adherence to AS – there is a need to combine our observations with qualitative studies to truly 
understand patterns of discontinuation [12]. Given the available data on the natural course of low 
risk disease, the question about whether active monitoring leads to better outcome and benefit 
whilst avoiding missing the window of cure in case of reclassification/progression is crucial. 
 
Conclusion 
Our descriptive analyses of current AS practices around the world showed that about 43.6% of 
men drop out of AS after 5 years, mainly due to signs of disease progression – about 12.8% of 
drop-outs were due to conversion to active treatment without evidence of progression. 
Improvements in selection tools for AS (e.g. biomarkers or MRI) are thus needed to correctly 
allocate men with PCa to AS – which in turn will also reduce discontinuation due to conversion 
to active treatment without evidence of disease progression.  
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Tables 
Table 1. Distribution of men on AS according to patient and tumour characteristics, by outcome following 
AS at 5 years of follow-up. The median and the inter-quartile range are provided for each variable.  
 
Variable Censor or Still on 
AS 
 (N = 7,049) 
Progression-
Treatment 
 (N = 2,061) 
Convert to active 
treatment without 
evidence of 
progression 
 (N = 952) 
Watchful Waiting 
(N=118) 
 
Other cause of 
Death 
 (N = 116) 
p-
value* 
Years on AS  3.3 (1.4, 5.8) 1.4 (1.1, 2.5) 1.6 (1.0, 2.7) 1.7 (1.2, 3.1) 2.3 (1.5, 3.4) <0.01 
Year of Diagnosis  2010 (2007, 2013) 2010 (2007, 2011) 2008 (2004, 2010) 2010 (2009, 2010) 2007 (2003, 2010) <0.01 
Age at start of AS (years) 65 (60, 69) 65 (61, 69) 65 (60, 69) 72 (65, 75) 69 (65, 73) <0.01 
PSA at start of AS  (ng/ml) 5.3 (3.9, 7.2) 5.4 (4.2, 7.0) 5.6 (4.2, 7.3) 5.9 (4.5, 7.5) 6.4 (4.2, 9.1) 0.01 
Number of biopsy cores 
with PCa  
1 (1, 2) 1 (1, 2) 1 (1, 2) 1 (1, 2) 1 (1, 2) <0.01 
* Kruskal-Wallis rank sum test 
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Table 2. Number of patients from each centre in GAP3 at 5 years of follow-up. 
 
Centre Still on 
AS 
Still on AS, 
follow-up < 
5 years 
Lost to 
follow-up 
Progression Converted to 
Active Treatment 
Watchful 
Waiting 
Death from 
other causes 
Total 
Atlanta 5 41 0 2 0 0 0 48 
Baden 44 52 0 22 24 2 1 145 
Calgary 82 346 0 80 30 0 0 538 
Cambridge 21 162 14 18 7 1 1 224 
Erasmus 
MC  
49 18 3 33 4 5 0 112 
PRIAS 
centres 
149 1368 26 392 136 51 13 2135 
Gothenburg 293 147 1 111 142 0 43 737 
Helsinki 58 97 1 97 9 17 3 282 
Hopkins 461 315 91 400 141 0 9 1417 
Kagawa 29 2 1 45 19 3 5 104 
Lille 4 94 10 36 10 0 1 155 
London-
KCL 
58 43 0 83 8 0 2 194 
London-
UCL 
30 230 0 0 10 2 0 272 
Malmo 10 90 1 19 4 1 1 126 
Melbourne 53 114 0 63 3 3 0 236 
Milan 102 287 0 245 51 23 2 710 
MSKCC 443 344 0 56 190 0 16 1049 
Seoul 0 33 0 2 1 0 0 36 
Singapore 21 93 0 20 46 0 1 181 
UCSF 405 487 0 262 94 0 11 1259 
Valencia 22 149 0 61 21 10 5 268 
Vancouver 0 49 1 14 2 0 2 68 
Total 2339 4561 149 2061 952 118 116 10296 
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Figures 
 
Figure 1. Cumulative incidence of discontinuation of active surveillance over time.  
 
Figure 2. Forest plot showing the association between age, PSA, positive biopsy cores and 
different reasons of discontinuation of active surveillance. 
 
Figure 3. Cumulative incidence of discontinuation of active surveillance over time for each 
centre in the GAP3 database.  
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Supplementary data 
 
Institute abbreviations:  
Monash - Monash University and Epworth Health, Melbourne, Australia; Kagawa -  Kagawa 
University Faculty of Medicine, Kagawa, Japan; Singapore -  Singapore General Hospital, 
Singapore; Seoul -  Gangnam Severance Hospital, Yonsei University Health System, Seoul, 
Republic of Korea; Helsinki -  Helsinki University Central Hospital, Helsinki, Finland; Gothenburg 
-  Sahlgrenska University Hospital, Göteborg, Sweden; Malmö -  Skåne University Hospital, 
Malmö, Sweden; Dublin -  University College Dublin, Dublin , Ireland; Erasmus -  Erasmus 
Medical Center, Rotterdam, the Netherlands; Lille -  Lille University Hospital Center, Lille, 
France; Baden -  Kantonsspital Baden, Baden, Switzerland; Milan -  Fondazione IRCCS Istituto 
Nazionale dei Tumori di Milano, Milan, Italy; Valencia -  Instituto Valenciano de Oncología, 
Valencia, Spain; Cambridge -  Cambridge University Hospitals NHS Trust, Cambridge, United 
Kingdom; KCL - King's College London, London, UK & Guy’s and St Thomas’ NHS Foundation 
Trust, London, United Kingdom; UCL - University College London & University College London 
Hospitals Trust, London, United Kingdom; Vancouver -  University of British Columbia , BC 
Cancer Agency, Vancouver, Canada); Calgary -  University of Calgary, Southern Alberta 
Institute of Urology, Calgary, Canada; Toronto -  University of Toronto, Sunnybrook Health 
Sciences Centre, Toronto, Canada; MSKCC -  Memorial Sloan Kettering Cancer Center, New 
York, USA; Hopkins - Johns Hopkins University, Baltimore, USA; MUSIC -  University of 
Michigan and Michigan Urological Surgery Improvement Collaborative, Michigan, USA; Emory -  
Emory University School of Medicine, Winship Cancer Institute, Atlanta, USA; MD Anderson -  
MD Anderson Cancer Centre, Houston, USA; UCSF -  University of California, San Francisco, 
San Francisco, USA
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Table S1. Inclusion criteria for Active Surveillance for each centre included in GAP3. 
NR=not reported 
 
 
  
Asia/Australia
Mona sh  >18 T1c or T2 ≤10 3+3=6 or 3+4=7, up to 20% of Pattern 4 <0.2 1- 2
≤5 mm per core (± equal 
25% of a core)
Ka ga wa 50- 80 T1cN0M0 ≤20 ≤3+3=6 NR 1- 2 per 6- 12 systematic biopsy cores ≤50%
Singa pore  >18 T1- T2 <10 3+3 NR NR ≤50%
Se oul  >18 T1- T2a ≤10 ≤7 NR <2 NR
Europe
He lsinki NR ≤T2 ≤10 ≤6 <0.2 1- 2 NR
Gothe nburg  >18 T1 <10 3+3=6 NR NR NR
Ma lmö  >18 T1c or T2 ≤10 3+3=6 or 3+4 <0.2 1- 2 NR
Dublin  >18 T1- T2a <10 ≤6 NR NR NR
Era smus NR ≤T2 ≤10 ≤6 <0.2 1- 2 NR
Lille  >18 T1c ≤15 3+3=6 or 3+4 NR ≤3 1- 5
Ba de n  >18 T1a- T1c (T2a) <10 ≤6 (3+3) NR ≤2 ≤5 mm/core
Mila n  >18
PRIAS: T1c- T2a; SAINT: 
T1c- T2a; T2b if ≤0.5 mL 
tumor volume and negative 
peripheral zone biopsy
≤10 3+3=6
PRIAS: <0.20; 
SAINT: NR
PRIAS: ≤2; ≤15% if saturation biopsy; 
No restriction if GS 3+3 fusion biopsy 
or negative RMmp; 
SAINT: ≤3 and ≤25% of total cores
PRIAS: X; 
SAINT: ≤50%
Va le nc ia <80 T1a, T1b, T1c ≤10 ≤6 or 3+4 (3+4 for men >70 years old) <0.2 ≤2 33% to ≤50%
UK
Ca mbridge 50- 75 T1- T2a ≤10 ≤6; 7 based on patient- c linical discussion NR NR NR
KCL  >18 T1a- T1b, T2 ≤15 ≤6 or ≤3+4=7 NR NR NR
UCL  >18 NR <20 Up to Gleason 7 No specific limit Targeted biopsy strategy used NR
United States
MSKCC  >18 NR NR 6 NR NR ≤50%
Hopkins >40 T1c, T2a
<10 (for men 
not meeting 
VLR criteria)
3+3=6
<0.15 to define VLR, 
and <0.1 if PSA over 
10ng/mL
2 or less
50% or less of any core, 
unless unilateral disease 
then NR
MUSIC  >18 T1- T2b ≤10 <7 NR ≤1/3 or all cores involved ≤50%
a) 3+3=6 a) <6 if 3+3=6
b) 3+4=7 with <10% of Pattern 4 if age >70 b) <3 if 3+4=7 
<4 3+3=6 ≤1 with <3mm tumor
<4 3+4=7 ≤1 with <2mm tumor
UCSF  >18 ≤T2 ≤10 ≤6 NR NR NR
Canada
<59 (stage I); ≤3 Stage I
>60 (stage II) <6 Stage II
≤10 ≤6
10- 20 3+4
Va nc ouve r NR ≤T2 ≤10 ≤6 <0.2 1- 2
Maximum of 50% or 5mm 
of PCa in a single core
Toronto  >18 NR NR NR <30%
Ca lga ry ≤T2 NR 6 (stage I or II): or 3+4 stage II NR <50%
Emory  >18 T1- T2 <10 <0.15 <50% any core
Positive  c ore s (n)
Min- ma x e xte nt 
c a nc e r pe r c ore s
MD Ande rson  >18 T1- T2 NR NR
Ce nte r Age  (ye a rs) Clinic a l sta ge
Se rum PSA 
(ng/ml)
Biopsy Gle a son  Sc ore
Se rum PSA de nsity 
(ng/ml/g)
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Table S2. Follow-up protocol for Active Surveillance for each centre included in GAP3. 
PSADT=PSA doubling time; PSAV=PSA velocity; DRE=Digital rectal exam; mpMRI=multi-parametric Magnetic resonance imaging; NR=not reported 
 
 
  
Ce nte r Se rum PSA
PSA Kine tic s 
(PSAD/PSAV)
DRE Biopsy mpMRI
Asia/Australia
Mona sh Every 3 months NR Every 6 months After months 12, 48, and 84 NR
Ka ga wa
Every 3 months for the first 6 
months, then every 3 months
NR Every 12 months Every 12 months NR
Singa pore
3- 6 monthly for the first 2 years, 
then 6- 12 monthly thereafter
Every 12 months Every 12 months Every 12 months Every 12 months
Se oul Every 3 months NR NR Considered if mpMRI result is changed Every 12 months
Europe
He lsinki Every 3 months Every 6 months Every 6 months After months 12, 48, and 84 NR
Gothe nburg Every 3- 6 months NR Every 6- 12 months Every 2- 3 years NR
Ma lmö Every 3 months NR Every 6 months After months 12, 48, and 84 NR
Dublin NR NR NR 1 year, than every other year. NR
Era smus Every 3 months Every 6 months Every 6 months After months 12, 48, and 84 NR
Lille Every 6 months NR Every 12 months At month 12 At month 12
Ba de n Every 6 months NR Every 6 months Every 24 months NR
Mila n Every 3 months NR Every 6 months
Every 12 months for the first 2 years and 
then every 24 months
NR
Va le nc ia Every 6 months NR Every 6 months
Month 24 from start on AS, then every 3 
years if no progression
NR
UK
Ca mbridge Every 3 months Every 12 months NR At Months 12, 36, 60 At Months 12, 36, 60
KCL Every 6 months Every 12 months Every 12 months NR Every 12 months
UCL
3- 4 monthly in 1 year; 6 monthly 
after that
NR Not routinely done
For men where there is a change in MRI 
and uncertainty about converting to 
active treatment
At baseline and 12 months for all men. After that, 
dependent on risk factors including MRI findings, 
PSA density and Gleason score.
United States
MSKCC Every 6 months NR Every 6 months Every 3 years Every 18 months
Hopkins Every 6 months NR Every 6 months Every 12 months NR
MUSIC Every 3- 6 months NR Every 12 months Every other year
Every other year; confirmatory test in first 3- 4 
months
Emory Every 6 months NR Every 12 months Every 12 months
Annually for the first 3 years, then final scheduled 
at 5 years
MD Ande rson Every 6 months NR Every 6 months Every 12 months Every 12 months
UCSF Every 3 months NR Every 6 months Every 12- 24 months NR
Canada
Va nc ouve r Every 3 months Every 6 months Every 6 months After months 12, 48, and 84 NR
Ca lga ry Every 6 months NR Every 6 months At year 1, then every 2 years When PSA>10
Toronto
Every 3 months until 2 years, then 
every 6 months
Every 12 months Every 6 months At Year 1, 4, 7, 10, and 15 Every 12 months
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Table S3. Patients and tumour characteristics of each centre at 5 years of follow-up. 
 
Variable Atlanta Baden Calgary Cambridge Erasmus MC 
 
PRIAS centres 
Years on AS (Median, range) 1.0 (0, 8.0) 3.5 (0, 11.5) 2.3 (0, 8.9) 2.1 (0, 9.6) 4.6 (0, 13.8) 1.5 (0, 8.5) 
Year of Diagnosis (Median, range) 2013 (2006, 2015) 2009 (2000, 2015) 2013 (2007, 2016) 2012 (2003, 2015) 2008 (2000, 2014) 2011 (2004, 2015) 
Age at start of AS (years; Median, range) 66 (41, 79) 67 (45, 78) 62 (42, 79) 66 (43, 79) 67 (49, 75) 66 (42, 79) 
PSA at start of AS (ng/ml; Median, range) 5.6 (1.8, 11) 4.7 (0.5, 19.6) 4.3 (0.2, 24.9) 6.8 (0.5, 29.2) 4.6 (0.3, 11) 5.8 (0.3, 16.7) 
Number of biopsy cores with PCa (Median, range) 1 (0, 7) NA 1 (0, 8) 1 (0, 20) 1 (0, 5) 1 (0, 10) 
Variable Gothenburg Helsinki Hopkins Kagawa Lille London-KCL 
Years on AS (Median, range) 3.8 (0, 17.4) 2.5 (0, 8) 3.1 (0, 18.8) 2.3 (0, 10.1) 1.4 (0, 6.7) 3 (0, 12) 
Year of Diagnosis (Median, range) 2005 (1995, 2015) 2010 (2006, 2016) 2008 (1992, 2014) 2003 (2002, 2003) 2012 (2007, 2015) 2009 (2003, 2012) 
Age  at start of AS(years; Median, range) 67 (51, 79) 63 (41, 78) 66 (41, 79) 70 (55, 79) 65 (43, 79) 63 (41, 79) 
PSA at start of AS  (ng/ml; Median, range) 4.6 (0.9, 29) 5.6 (0.9, 10) 4.8 (0.2, 27.6) 6.5 (2.1, 15.9) 6.5 (1.1, 25) 6 (1, 27) 
Number of biopsy cores with PCa (Median, range) 1 (1, 10) 1 (0, 9) 1 (0, 11) 1 (0, 7) 1 (0, 15) 2 (0, 18) 
Variable London-UCL Malmo Melbourne Milan MSKCC Seoul 
Years on AS (Median, range) 0 (0, 8) 1.7 (0, 6.7) 2.5 (0, 10) 2.1 (0, 9.9) 4.4 (0, 16.8) 1.3 (0.1, 4.2) 
Year of Diagnosis (Median, range) 2009 (2001, 2013) 2012 (2007, 2014) 2009 (2003, 2013) 2011 (2004, 2015) 2008 (1993, 2011) 2015 (2011, 2016) 
Age at start of AS (years; Median, range) 62 (44, 78) 66 (48, 78) 63 (45, 79) 66 (42, 79) 63 (41, 79) 68 (50, 79) 
PSA at start of AS  (ng/ml; Median, range) 6.3 (0.4, 24.6) 5.1 (2.4, 10.7) 5.9 (0.3, 26.1) 5.7 (0.3, 22.7) 4.6 (0, 22) 5.0 (0.7, 20.6) 
Number of biopsy cores with PCa (Median, range) 2 (1, 6) 1 (0, 5) 2 (0, 15) 1 (0, 8) 1 (0, 13) NA 
Variable Singapore UCSF Valencia Vancouver   
Years on AS (Median, range) 2.5 (0.5, 9.1) 3.3 (0.5, 20.4) 1.6 (0, 13.6) 1.8 (0, 4.4)   
Year of Diagnosis (Median, range) 2011 (2000, 2014) 2009 (1993, 2015) 2012 (2001, 2016) 2007 (2004, 2009)   
Age at start of AS (years; Median, range) 66 (47, 79) 62 (41, 79) 66 (41, 79) 67 (49, 77)   
PSA at start of AS (ng/ml; Median, range) 6.3 (0.1, 29.3) 5.4 (0.3, 28.2) 5.4 (0.9, 28.9) 5.4 (0.7, 11.6)   
Number of biopsy cores with PCa (Median, range) 1 (0, 15) 2 (0, 16) 1 (0, 12) 1 (0, 4)   
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APENDIX A 
 
*Members of The Movember Foundation’s Global Action Plan Prostate Cancer Active 
Surveillance (GAP3) consortium 
 
